Todos intends to acquire Provista and fund the EBV

Todos intends to acquire Provista and fund the EBV study to satisfy CMS and establish a unique CPT code for Videssa. It is possible that CMS may grant limited CPT code based upon the preliminary data that Provista will present in discussions with CMS so that a present number of Videssa tests may be reimbursed to offset the financial burden of running the clinical utility study, and Todos’ team is working closely with Provista’s team to engage with CMS in those discussions, although there are no assurances that any such limited reimbursement will occur. As part of the clinical utility study, Todos intends to piggyback data gathering for the Todos breast cancer tests based upon specimens gathered for the Videssa clinical utility study, which would have the effect of dramatically increasing the quantity of data available for the Todos breast cancer tests Therefore, upon the Company’s acquisition of Provista, the Company may be able to accelerate the timeline pursuant to which the Company may be able to bring the Todos blood tests to the market as a result of working closely with the Videssa tests in United States which management believes is in the best interests of the Company’s shareholders. 

P11. 

https://ir.stockpr.com/todosmedical/sec-filin...ex99-1.htm